Before biotech companies have sales to report to investors, their share prices often live and die on the enthusiasm they can build about their ongoing clinical trials. And when those trials disappoint ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader. There's still plenty of work left to do ...

View Structure Therapeutics, Inc. Sponsored ADR GPCR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Encouraging phase 2 results convinced Evan Seigerman at BMO Capital Markets to raise his price target on the stock to $100 per share. The new target implies an 87% gain from recent prices. The market ...

ACT Capital Management sold 38,500 shares of Structure Therapeutics in the first quarter; the estimated transaction value was $2.63 million based on Q1 2026 average prices. The quarter-end position ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure Therapeutics (NASDAQ: GPCR), skyrocketed almost 103% higher in price that day on ...